LymphomaNCT05464823
Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma
A study testing Molecular Functional Portrait in people with Lymphoma, run by M.D. Anderson Cancer Center at 1 site in United States.
Trial summary
To learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Lymphoma
- What is being tested?
- Molecular Functional Portrait
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 111 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Jul 2022to 12 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male/female patients who are at least 18 years of age on the day of informed consent signing.
- Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy.
- Provision of written informed consent for the study.
Who cannot join
- 1. None
Trial locations and contacts
1 site in 1 country.
About this study
To learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.
Read the detailed description
Primary Objective:
- To determine the feasibility and turnaround of clinical WES and transcriptome sequencing
Secondary Objectives:
- To determine the frequency of actionable DNA and RNA alterations
- To determine the concordance of DNA and RNA alterations
- To determine the frequency of molecularly matched therapy
- To determine the feasibility of identifying mechanism(s) of acquired resistance with genomic profiling
- To determine the feasibility of molecularly matched therapy to acquired resistance alterations
Exploratory Objectives:
- To determine the feasibility of prioritizing targets with precision analytics
- To determine clinical outcomes in patients receiving molecularly matched therapy
- To determine the role of additional emerging diagnostic technologies
- Conditions
- Lymphoma
- Being tested
- Molecular Functional Portrait
- Medical subject headings
- Lymphoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Molecular Functional PortraitOther
Participants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test
| Study group | Role | What they receive |
|---|---|---|
| Molecular Testing | Other | Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care. Receives: Other: Molecular Functional Portrait |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of participants who have genomic test results available in <=7 days
Measured: through study completion an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jul 2022
- Study start7 Jul 2022
- Primary completion12 May 2027 (estimated)
- Study completion12 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for LymphomaStudies of the same condition, open and under way.
- More trials run by M.D. Anderson Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 111 participants (actual)
Sponsor and investigators
- Lead sponsor
- M.D. Anderson Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jason Westin, MD, Principal investigator, M.D. Anderson Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05464823
- Sponsor's protocol ID
- 2022-0396
- Other IDs
- NCI-2022-05783
- Status last verified
- Aug 2026
- First submitted
- 12 Jul 2022
- Last updated
- 14 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Chihara D, Balakrishnan K, Masand G, Harkins RA, Akkad N, Alekseeva E, Nesmelov A, Shugaev-Mendosa E, Anosov I, Rusinov A, Postovalova E, Gracheva Y, Lauziere K, Paradiso F, Kotlov N, Bagaev A, Green MR, Fowler NH, Flowers CR, Westin JR. Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma. Blood Adv. 2026 Nov 10;10(21):7383-7392. doi: 10.1182/bloodadvances.2025019468.
PubMed 42498283
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma
- ClinicalTrials.gov ID
- NCT05464823
- Acronym / sponsor ID
- 2022-0396
- Conditions
- Lymphoma
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 111 participants (actual)
- Lead sponsor
- M.D. Anderson Cancer CenterUniversity, hospital or other
- Study start
- 7 Jul 2022 (actual)
- Primary completion
- 12 May 2027 (estimated)
- Study completion
- 12 May 2027 (estimated)
- First posted
- 19 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.
Detailed description
Primary Objective:
- To determine the feasibility and turnaround of clinical WES and transcriptome sequencing
Secondary Objectives:
- To determine the frequency of actionable DNA and RNA alterations
- To determine the concordance of DNA and RNA alterations
- To determine the frequency of molecularly matched therapy
- To determine the feasibility of identifying mechanism(s) of acquired resistance with genomic profiling
- To determine the feasibility of molecularly matched therapy to acquired resistance alterations
Exploratory Objectives:
- To determine the feasibility of prioritizing targets with precision analytics
- To determine clinical outcomes in patients receiving molecularly matched therapy
- To determine the role of additional emerging diagnostic technologies
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Molecular Testing | Other | Other: Molecular Functional PortraitMolecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Male/female patients who are at least 18 years of age on the day of informed consent signing.
- Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy.
- Provision of written informed consent for the study.
Key exclusion criteria (1 listed)
- 1. None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Molecular Functional PortraitParticipants will be asked to allow previously-collected tumor tissue to be used for the MF Portrait test | Other | Molecular Testing |
Primary outcome
Percentage of participants who have genomic test results available in <=7 days
Time frame: through study completion an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
- Derived from this study: PubMed 42498283Chihara D, Balakrishnan K, Masand G, Harkins RA, Akkad N, Alekseeva E, Nesmelov A, Shugaev-Mendosa E, Anosov I, Rusinov A, Postovalova E, Gracheva Y, Lauziere K, Paradiso F, Kotlov N, Bagaev A, Green MR, Fowler NH, Flowers CR, Westin JR. Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma. Blood Adv. 2026 Nov 10;10(21):7383-7392. doi: 10.1182/bloodadvances.2025019468.
- M D Anderson Cancer CenterLink provided by the sponsor.
Related trials for Lymphoma
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
RecruitingPhase 2
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Non-hodgkin Lymphoma
RecruitingObservational study
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
Cutaneous T-cell Lymphoma, Sezary Syndrome
Not yet recruitingPhase 1
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma
Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma
Active, not recruitingPhase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jason Westin, MD principal investigator
M.D. Anderson Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Molecular Functional Portrait in people with Lymphoma, run by M.D. Anderson Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of participants who have genomic test results available in <=7 days (time frame: through study completion an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05464823, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.